Biomarkers for the diagnosis and treatment of rheumatoid arthritis – a systematic review

Abdelhafiz, Dima; Baker, T; Glascow, DA; Abdelhafiz, AH

doi:10.1080/00325481.2022.2052626

Cited by 24 publications

(13 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are in line with the results of the studies included in our systematic review and also with the results of the previous meta-analysis by Curtis et al [ 53 ] and the systematic review by Abdelhafiz et al . [ 54 ]. The limitation of both our study and the study by Curtis et al [ 53 ] is the lack of included studies investigating the efficacy of DAS28-CRP for predicting radiographic progression independent of the MBDA score, potentially leading to biased results.…”

Section: Discussionmentioning

confidence: 99%

Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Objectives The multi-biomarker disease activity (MBDA) score is an objective tool for monitoring disease activity in rheumatoid arthritis (RA). Here we report a systematic review and meta-analysis of the clinical value of the MBDA score in RA. Methods We performed a systematic literature search in five medical databases: MEDLINE (via PubMed), Cochrane Library (CENTRAL), Embase, Scopus, and Web of Science, from inception to 13 October 2021. Original articles reporting on the performance of the MBDA score’s correlation with conventional disease activity measures, or the predictive and the discriminative value of the MBDA score for radiographic progression, therapy response, remission, and relapse were included. Results Our systematic search provided a total of 1190 records. After selection and citation searches, we identified 32 eligible studies. We recorded moderate correlations between MBDA score and conventional DAMs at baseline (COR = 0.45, CI: 0.28–0.59; I2 = 71.0% for DAS28 CRP and COR = 0.55, CI: 0.19–0.78; I2 = 0.0% for DAS28-ESR) and at follow-up (COR = 0.44, CI: 0.28–0.57; I2 = 70.0% for DAS28 CRP), and found that the odds of radiographic progression were significantly higher for patients with a high baseline MBDA score (>44) than for patients with a low baseline MBDA score (<30) (OR = 1.03, CI: 1.02–1.05; I2 = 10.0%). Conclusion MBDA score might be used as an objective disease activity marker. In addition, it is also a reliable prognostic marker of radiographic progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Patient global assessment—included in the MSRC feature set—considers disease activity and complex underlying factors such as pain, depression, anxiety, and inability to participate in daily activities [ 34 ]. Numerous additional studies [ 35 , 36 ], a review of which are beyond the scope of this letter, evaluated the likelihood of treatment success with TNFi in RA, yet a clinically useful model predicting TNFi therapeutic outcomes from routine clinical assessments alone has not been achieved.…”

Section: Main Commentarymentioning

confidence: 99%

Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis

Cohen

Curtis

Mellors³

et al. 2022

Rheumatol Ther

View full text Add to dashboard Cite

A 2021 study described the development and validation of a blood-based precision medicine test called the molecular signature response classifier (MSRC) that uses 23 features to identify rheumatoid arthritis (RA) patients who are likely nonresponders to tumor necrosis factor-a inhibitor (TNFi) therapy. Both the gene expression features and clinical components (sex, body mass index, patient global assessment, and anti-cyclic citrullinated protein) included in the MSRC were statistically significant contributors to MSRC results. In response to continued inquiries on this topic, we write this letter to provide additional insights into the contribution of clinical components to the MSRC on the Network-004 validation cohort.

show abstract

“…Despite extensive research efforts, the pathogenesis of RA remains incompletely understood, with complex interactions between genetic, environmental, and immunological factors likely playing a role in its development (3,4). Furthermore, current diagnostic methods for RA are still suboptimal, highlighting the need for reliable and efficient biomarkers to improve patient outcomes (5).…”

Section: Introductionmentioning

confidence: 99%

Platelets-related signature based diagnostic model in rheumatoid arthritis using WGCNA and machine learning

Liu,

Jiang,

Kang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Background and aimRheumatoid arthritis (RA) is an autoinflammatory disease that may lead to severe disability. The diagnosis of RA is limited due to the need for biomarkers with both reliability and efficiency. Platelets are deeply involved in the pathogenesis of RA. Our study aims to identify the underlying mechanism and screening for related biomarkers.MethodsWe obtained two microarray datasets (GSE93272 and GSE17755) from the GEO database. We performed Weighted correlation network analysis (WGCNA) to analyze the expression modules in differentially expressed genes identified from GSE93272. We used KEGG, GO and GSEA enrichment analysis to elucidate the platelets-relating signatures (PRS). We then used the LASSO algorithm to develop a diagnostic model. We then used GSE17755 as a validation cohort to assess the diagnostic performance by operating Receiver Operating Curve (ROC).ResultsThe application of WGCNA resulted in the identification of 11 distinct co-expression modules. Notably, Module 2 exhibited a prominent association with platelets among the differentially expressed genes (DEGs) analyzed. Furthermore, a predictive model consisting of six genes (MAPK3, ACTB, ACTG1, VAV2, PTPN6, and ACTN1) was constructed using LASSO coefficients. The resultant PRS model demonstrated excellent diagnostic accuracy in both cohorts, as evidenced by area under the curve (AUC) values of 0.801 and 0.979.ConclusionWe elucidated the PRSs occurred in the pathogenesis of RA and developed a diagnostic model with excellent diagnostic potential.

show abstract

Biomarkers for the diagnosis and treatment of rheumatoid arthritis – a systematic review

Cited by 24 publications

References 64 publications

Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis

Multibiomarker disease activity score: an objective tool for monitoring rheumatoid arthritis? A systematic review and meta-analysis

Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis

Platelets-related signature based diagnostic model in rheumatoid arthritis using WGCNA and machine learning

Contact Info

Product

Resources

About